ArticleInternational journal of endocrinology2026
Clinical Utility of Urinary Cystatin C in Early Screening and Staging of Diabetic Kidney Disease in Type 2 Diabetes.
Article in International journal of endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biomarkers in Diabetic Kidney Disease: Early Detection, Prognostic Assessment, and Integration with Multi-Omics Signatures.Life (Basel, Switzerland) · 2026Review
- Clinical Utility of Urinary Cystatin C in Early Screening and Staging of Diabetic Kidney Disease in Type 2 Diabetes.International journal of endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Diabetic kidney disease (DKD) is a major complication of Type 2 diabetes mellitus (T2DM). Early detection is critical to prevent renal function decline and improve outcomes, but conventional biomarkers (e.g., urinary albumin-to-creatinine ratio [UACR] and estimated glomerular filtration rate [eGFR]) have limited sensitivity for early-stage kidney damage. Urinary cystatin C (UcyC) is a protein marker of impaired tubular reabsorption and a promising biomarker for early tubulointerstitial injury in DKD. This study assessed the clinical utility of UcyC for early detection and staging of DKD and compared its diagnostic performance with that of serum cystatin C (CysC). Methods: This prospective study included 102 patients with T2DM who were enrolled at The People's Hospital of Chizhou, China, between May 2022 and October 2025. The participants were classified as having T2DM without kidney disease (T2DM without KD) or DKD based on UACR and eGFR. The DKD group was divided into early DKD (EDKD) and clinical DKD (CDKD). Demographic and laboratory data were obtained from the hospital's medical records. Multivariate logistic regression analyses independent risk factors of DKD. Correlation analysis and receiver operating characteristic (ROC) curve analyses assess diagnostic accuracy and disease staging effectiveness of DKD. Results: Compared with T2DM individuals free of renal complications, DKD patients showed significantly elevated UcyC concentrations ( Conclusion: UcyC, a noninvasive and highly sensitive biomarker for renal injury, could be valuable for early screening, assessing risk levels, and potentially guiding treatment personalization in DKD. This may streamline diagnosis and help tailor management plans for patients with DKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.